| Literature DB >> 17876005 |
D Bradshaw1, S Malik, C Booth, M Van Houtte, T Pattery, A Waters, J Ainsworth, A M Geretti.
Abstract
We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17876005 PMCID: PMC2167988 DOI: 10.1128/AAC.00687-07
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191